Monographie - Filgrastim - Stabilis 4.0

Seneste opdatering :
19/11/2024

Diverse

Filgrastim

Injektion

Stabilitet i (vandige) opløsninger

Stabilitet i blandinger

Faktorer der påvirker stabiliteten

Kompatibilitet

Administrationsvej

Bibliografi

pdf

Handelsnavn

Handelsnavn

Handel navne er vejledende og hjælpestoffer sammensætning kan være forskellig afhængigt af landet og laboratorier

Accofil	Belgien, Storbritanien, Tyskland
Biocilin	Mexico
Duperan	Chile
Filgen	Argentina
Foltran	Chile
Granulokine	Grækenland, Italien
Hebervital	Colombia
Inmunef	Colombia
Leucosos	Colombia
Lioplim	Chile
Neupogen	Belgien, Danmark, Finland, Frankrig, Holland, Kroatien, Polen, Portugal, Schweiz, Slovenien, Spanien, Storbritanien, Sverige, Sydafrika, Tyrkiet, USA, Østrig
Neutromax	Argentina
Neutropine	Argentina
Nivestim	Belgien, Frankrig, Holland, Norge, Storbritanien, Tyskland
Ratiograstim	Storbritanien, Sverige, Tyskland, Østrig
Tevagrastim	Holland, Norge, Schweiz, Storbritanien, Sverige, Tyskland

Bibliografi

Injektion

Bibliografi : Filgrastim

	Type	offentliggørelse
99	Journal	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
104	Journal	Hall PD, Yui D, Lyons S, Bosso JA. Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 185-189.
182	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Journal	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
2269	Journal	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3128	Laboratorium	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3249	Journal	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3256	Journal	Burnett B, Radic I. Stability of Hospira filgrastim following changes to thermal and photic storage conditions. EJHP 2011 ; 17, 5: 49-56.
3474	Laboratorium	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3618	Laboratorium	Filgrastim (Neupogen®) - Summary of Product Characteristics Amgen 2014
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	Journal	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4380	Laboratorium	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4471	Laboratorium	Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 Kyowa Kirin Pharma 2019
4521	Journal	Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020
4650	Laboratorium	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021

Mentions Légales